Yifan Pharmaceutical (002019.SZ): N-3C01 injection approved for clinical trials.
Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Hefei Xinzhu Biotechnology Co., Ltd. (referred to as "Hefei Xinzhu"), recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. This approval allows Hefei Xinzhu to conduct clinical trials on the investigational new large molecule drug N-3C01 injection (referred to as "N-3C01") for the treatment of advanced solid tumors and non-muscle-invasive bladder cancer (NMIBC).
Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Hefei Xinzhu Biotechnology Co., Ltd. (referred to as "Hefei Xinzhu"), recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. The approval allows Hefei Xinzhu to conduct clinical trials on the investigational new macromolecular drug N-3C01 injection (referred to as "N-3C01") for the treatment of advanced solid tumors and non-muscle-invasive bladder cancer (NMIBC).
Related Articles
Tianqi Lithium Corporation (09696) applies for designation as a delivery warehouse for lithium hydroxide at the Guangzhou Futures Exchange.
Jiangsu Kanion Pharmaceutical (600557.SH): The domestic first generic drug simvastatin and ezetimibe sodium tablets have been included in the national medical insurance list.
Shareholder Jiangsu Baixing of Lifecome Biochemistry (002868.SZ) plans to reduce its shareholding by no more than 3%.
Tianqi Lithium Corporation (09696) applies for designation as a delivery warehouse for lithium hydroxide at the Guangzhou Futures Exchange.
Jiangsu Kanion Pharmaceutical (600557.SH): The domestic first generic drug simvastatin and ezetimibe sodium tablets have been included in the national medical insurance list.
Shareholder Jiangsu Baixing of Lifecome Biochemistry (002868.SZ) plans to reduce its shareholding by no more than 3%.
